Rigel Pharmaceuticals, Inc. RIGL
NASDAQ · United States · Health Technology
$48.30+0.15 (+0.30%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Recently published Myelodysplastic Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, myelodysplastic syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will participate in the following investor conferences in September:
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
The latest analyst update on Rigel Pharmaceuticals centers on a higher assessed fair value, which has moved from US$51.6 to US$61.2 per share in the current model. Analysts link this shift to how they view Veppanu in the U.S. and the ex U.S. potential of Rezlidhia under the Kissei partnership, with both products seen as key to supporting or challenging the new valuation. As you read on, you will see how to track this evolving narrative and what it could mean for your own view of Rigel...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.